+44 (0) 1793 575 050
customerservice@regenmedical.co.uk

Part of the Joint Operations family

    GET IN TOUCH TO FIND OUT MORE

    Nexodyn® AOS AcidOxidising Solution  – The Wound Closure Cleanser

    Nexodyn® AcidOxidizing Solution (AOS) is the Tehclo™ based cleanser is proven to restart healing in stalled wounds, supporting:

    1. Faster healing time
    2. Potection from risk of infection
    3. Reduced wound associated pain

    Wound cleanser choice is key to promoting healing

     

    Wound Bed Preparation: an evidence-based approach

    There is a critical need for evidence to support efficacy in wound closure with minimal impact on patients, particularly for Wound Bed Preparation. (8)

    According to EWMA and WHO guidelines, Wound Bed Preparation aims to remove local barriers to healing promoting wound closure through diagnosis, appropriate treatment of the cause and attention to patient-centered concerns. (9,10)

    The ideal cleanser choice

    Wound cleansers have been historically used solely to remove contaminants, foreign debris and exudate.

    Today, wound cleansing has become recognised as a fundamental step of Wound Bed Preparation with the potential to promote healing by removing local barriers to healing,(10,11) while at the same time minimising the harm to wound tissue.11
    The cleanser solutions available on the market have several limitations and traditional cleansing agents have not been shown to have efficacy in wound care. (8)

    How Nexodyn fits in – An active wound cleanser

    Adding Nexodyn® AOS to the standard of care for diabetic foot ulcers results in faster healing time and protection from risk of infection (12*)

    1. Healing time was significantly reduced in the group receiving Nexodyn® AOS (12)
    2. Significant protection from risk of infection (12)

    Nexodyn AOS reduces clinical signs of local infection and wound associated pain in leg ulcers (13**)

    1. Significant reduction of clinical signs of local infection (13)
    2. Wound-associated pain was significantly reduced over time (13)

    Nexodyn® AOS is well tolerated No adverse events associated with the use of Nexodyn® AOS were reported in any of the reported studies. (12,13,14)

    A wealth of evidence and real-world experience consistently show that Nexodyn® AOS reduces healing time, protects from risk of infection, reduces clinical signs of local infection and wound associated pain with a highly tolerable profile.(12,13,14)

    What is the technology behind Nexodyn® AOS?

    Tehclo™ is the APR proprietary globally patented nanotechnology platform that applies nanoscience to the production of a unique hypochlorous acid (HClO) solution.

    Hypochlorous acid is well-known as a broad-spectrum, fast acting antimicrobial agent naturally produced by neutrophils as part of the innate immune system’s response to infections.15,16

    Unique combination of 3 physicochemical properties:

    Nexodyn® AOS in practice

    Nexodyn® AOS is a sprayable solution for Wound Care with ancillary antimicrobial properties intended for use in the debridement, irrigation, cleansing and moistening of chronic wounds and acute wounds, post-surgical wounds, cuts, abrasions, burns and other lesions.(1)

    Based on Tehclo™, Nexodyn® AOS is the newly conceived solution that maximizes efficacy and safety:

    CE marked Medical Device

    Sizing & Product Codes

    Currently available in:

    • 0APH70050090/1 – 100 ml bottle with dispenser
    • 0APH70050090 – Boxes of 12
    • Minimum order quantity – box of 12
    • 50ml, 250ml and 500ml are planned shortly
    Nexodyn AOS Indications for Use and Contra-Indications
    References

    1. Nexodyn® AcidOxidizing Solution (AOS) [package insert]. Balerna, Switzerland: APR, Applied Pharma Research SA; 2015. 2. Han G, Ceilley R. Chronic Wound Healing: A Review of Current Management and Treatments. Adv Ther. 2017;34(3):599–610. doi:10.1007/s12325-017-0478-y. 3a. Avishai E, Yeghiazaryan K, Golubnitschaja O. Impaired wound healing: facts and hypotheses for multi-professional considerations in predictive, preventive and personalised medicine. EPMA J. 2017;8(1):23–33. Published 2017 Mar 3.doi:10.1007/s13167-017-0081-y. 3b. Azzimonti B. et al, Therapies and Regeneration, 2016, Vol 1. Pages 101-116. 4. Frykberg RG, Banks J. Challenges in the Treatment of Chronic Wounds. Advances in wound care. 2015;4(9):560-82. 5. Kirker KR, James GA. In vitro studies evaluating the effects of biofilms on wound-healing cells: a review. APMIS : Acta Pathologica, Microbiologica, et Immunologica Scandinavica. 2017;125(4):344-52. 6. Barrett S. Wound-bed preparation: a vital step in the healing process. Br J Nurs. 2017 26(12 Suppl):S24-S31. doi: 10.12968/bjon.2017.26.12.S24. 7. Renner R. Depression and quality of life in patients with chronic wounds: ways to measure their influence and their effect on daily life. Chronic Wound Management and Research. 2017;4:143-151. 8. Munro, G. Causes and consideration with chronic wounds: A narrative review of the evidence [online]. Wound Practice & Research: Journal of the Australian Wound Management Association. Vol. 25, No. 2, Jun 2017: 88-97. 9. Macdonald, John M, Geyer, Mary Jo & World Health Organization.Wound and lymphoedema management.2010. 10. European Wound Management Association (EWMA). Position Document: Wound Bed Preparation in Practice. London: MEP Ltd, 2004. 11. McLain NEM, Moore ZEH. Wound cleansing for treating venous leg ulcers. Cochrane Database of Systematic Reviews 2015, Issue 4. Art. No.: CMcLainD011675.e: NEM. 11b. Wounds International 2014 Vol 1 Issue 1 ©Wounds International 2014. 12. Iacopi E. et al. The Use of a Novel Super-Oxidized Solution on Top of Standard Treatment in the Home Care Management of Postsurgical Lesions of the Diabetic Foot Reduces Reinfections and Shortens Healing Time. Int J Low Extrem Wounds. 2018 Dec; 17(4):268-274. 13. Strohal R, et al. The management of critically colonized and locally infected leg ulcers with an Acid-Oxidizing Solution: A pilot study. Adv Skin Wound Care 31(4):163-171, 2018. 14. Ricci E, et al. The management of chronic ulcers with an AcidOxidizing Solution. J Wound Care 25(8):443-50, 2016. 15. Rani SA, Hoon R, Najafi RR, Khosrovi B, Wang L, Debabov D. The in vitro antimicrobial activity of wound and skin cleansers at nontoxic concentrations. Advances in skin & wound care. 2014;27:65-69. 16. Woods CG, Fu J, Xue P, et al. Dose-dependent transitions in Nrf2-mediated adaptive response and related stress responses to hypochlorous acid in mouse macrophages. Toxicology and applied pharmacology. 2009;238:27-36.

    *Independent experience in a diabetic foot excellence center showed the benefit of adding Nexodyn® AOS to the standard of care. In this prospective and comparative study, 50 patients with post-surgical, non-ischemic and non-infected lesions were followed up until complete healing or up to 6 months. The Nexodyn® AOS group (n=25) received Nexodyn® AOS on top of the standard treatment, while the SOC group (n=25) received only the standard treatment.

    **In a prospective, single arm study of 30 patients with critically colonized or locally infected leg ulcers of different etiology, Nexodyn® AOS was sprayed twice to cover the whole wound, at every dressing change for 5 weeks.13 After 2 applications, a non-adherent gauze was soaked with Nexodyn® AOS and applied on the wound surface, then covered with an all-purpose absorbent dressing.13

    Nexodyn® – The Wound Closure Cleanser (AOS – AcisOxidising Solution)

    Nexodyn® AcidOxidizing Solution (AOS) is the Tehclo™ based cleanser proven to restart healing in stalled wounds.

    1. Faster healing time
    2. Potection from risk of infection
    3. Reduced wound associated pain

    Wound cleanser choice is key to promoting healing

     

    Wound Bed Preparation: an evidence-based approach

    There is a critical need for evidence to support efficacy in wound closure with minimal impact on patients, particularly for Wound Bed Preparation. (8)

    According to EWMA and WHO guidelines, Wound Bed Preparation aims to remove local barriers to healing promoting wound closure through diagnosis, appropriate treatment of the cause and attention to patient-centered concerns. (9,10)

    The ideal cleanser choice

    Wound cleansers have been historically used solely to remove contaminants, foreign debris and exudate.

    Today, wound cleansing has become recognised as a fundamental step of Wound Bed Preparation with the potential to promote healing by removing local barriers to healing,(10,11) while at the same time minimising the harm to wound tissue.11
    The cleanser solutions available on the market have several limitations and traditional cleansing agents have not been shown to have efficacy in wound care. (8)

    How Nexodyn fits in – An active wound cleanser

    Adding Nexodyn® AOS to the standard of care for diabetic foot ulcers results in faster healing time and protection from risk of infection (12*)

    1. Healing time was significantly reduced in the group receiving Nexodyn® AOS (12)
    2. Significant protection from risk of infection (12)

    Nexodyn AOS reduces clinical signs of local infection and wound associated pain in leg ulcers (13**)

    1. Significant reduction of clinical signs of local infection (13)
    2. Wound-associated pain was significantly reduced over time (13)

    Nexodyn® AOS is well tolerated No adverse events associated with the use of Nexodyn® AOS were reported in any of the reported studies. (12,13,14)

    A wealth of evidence and real-world experience consistently show that Nexodyn® AOS reduces healing time, protects from risk of infection, reduces clinical signs of local infection and wound associated pain with a highly tolerable profile.(12,13,14)

    What is the technology behind Nexodyn® AOS?

    Tehclo™ is the APR proprietary globally patented nanotechnology platform that applies nanoscience to the production of a unique hypochlorous acid (HClO) solution.

    Hypochlorous acid is well-known as a broad-spectrum, fast acting antimicrobial agent naturally produced by neutrophils as part of the innate immune system’s response to infections.15,16

    Unique combination of 3 physicochemical properties:

    Nexodyn® AOS in practice

    Nexodyn® AOS is a sprayable solution for Wound Care with ancillary antimicrobial properties intended for use in the debridement, irrigation, cleansing and moistening of chronic wounds and acute wounds, post-surgical wounds, cuts, abrasions, burns and other lesions.(1)

    Based on Tehclo™, Nexodyn® AOS is the newly conceived solution that maximizes efficacy and safety:

    CE marked Medical Device

    Sizing & Product Codes

    Currently available in:

    • 0APH70050090/1 – 100 ml bottle with dispenser
    • 0APH70050090 – Boxes of 12
    • Minimum order quantity – box of 12
    • 50ml, 250ml and 500ml are planned shortly
    Nexodyn AOS Indications for Use and Contra-Indications
    References

    1. Nexodyn® AcidOxidizing Solution (AOS) [package insert]. Balerna, Switzerland: APR, Applied Pharma Research SA; 2015. 2. Han G, Ceilley R. Chronic Wound Healing: A Review of Current Management and Treatments. Adv Ther. 2017;34(3):599–610. doi:10.1007/s12325-017-0478-y. 3a. Avishai E, Yeghiazaryan K, Golubnitschaja O. Impaired wound healing: facts and hypotheses for multi-professional considerations in predictive, preventive and personalised medicine. EPMA J. 2017;8(1):23–33. Published 2017 Mar 3.doi:10.1007/s13167-017-0081-y. 3b. Azzimonti B. et al, Therapies and Regeneration, 2016, Vol 1. Pages 101-116. 4. Frykberg RG, Banks J. Challenges in the Treatment of Chronic Wounds. Advances in wound care. 2015;4(9):560-82. 5. Kirker KR, James GA. In vitro studies evaluating the effects of biofilms on wound-healing cells: a review. APMIS : Acta Pathologica, Microbiologica, et Immunologica Scandinavica. 2017;125(4):344-52. 6. Barrett S. Wound-bed preparation: a vital step in the healing process. Br J Nurs. 2017 26(12 Suppl):S24-S31. doi: 10.12968/bjon.2017.26.12.S24. 7. Renner R. Depression and quality of life in patients with chronic wounds: ways to measure their influence and their effect on daily life. Chronic Wound Management and Research. 2017;4:143-151. 8. Munro, G. Causes and consideration with chronic wounds: A narrative review of the evidence [online]. Wound Practice & Research: Journal of the Australian Wound Management Association. Vol. 25, No. 2, Jun 2017: 88-97. 9. Macdonald, John M, Geyer, Mary Jo & World Health Organization.Wound and lymphoedema management.2010. 10. European Wound Management Association (EWMA). Position Document: Wound Bed Preparation in Practice. London: MEP Ltd, 2004. 11. McLain NEM, Moore ZEH. Wound cleansing for treating venous leg ulcers. Cochrane Database of Systematic Reviews 2015, Issue 4. Art. No.: CMcLainD011675.e: NEM. 11b. Wounds International 2014 Vol 1 Issue 1 ©Wounds International 2014. 12. Iacopi E. et al. The Use of a Novel Super-Oxidized Solution on Top of Standard Treatment in the Home Care Management of Postsurgical Lesions of the Diabetic Foot Reduces Reinfections and Shortens Healing Time. Int J Low Extrem Wounds. 2018 Dec; 17(4):268-274. 13. Strohal R, et al. The management of critically colonized and locally infected leg ulcers with an Acid-Oxidizing Solution: A pilot study. Adv Skin Wound Care 31(4):163-171, 2018. 14. Ricci E, et al. The management of chronic ulcers with an AcidOxidizing Solution. J Wound Care 25(8):443-50, 2016. 15. Rani SA, Hoon R, Najafi RR, Khosrovi B, Wang L, Debabov D. The in vitro antimicrobial activity of wound and skin cleansers at nontoxic concentrations. Advances in skin & wound care. 2014;27:65-69. 16. Woods CG, Fu J, Xue P, et al. Dose-dependent transitions in Nrf2-mediated adaptive response and related stress responses to hypochlorous acid in mouse macrophages. Toxicology and applied pharmacology. 2009;238:27-36.

    *Independent experience in a diabetic foot excellence center showed the benefit of adding Nexodyn® AOS to the standard of care. In this prospective and comparative study, 50 patients with post-surgical, non-ischemic and non-infected lesions were followed up until complete healing or up to 6 months. The Nexodyn® AOS group (n=25) received Nexodyn® AOS on top of the standard treatment, while the SOC group (n=25) received only the standard treatment.

    **In a prospective, single arm study of 30 patients with critically colonized or locally infected leg ulcers of different etiology, Nexodyn® AOS was sprayed twice to cover the whole wound, at every dressing change for 5 weeks.13 After 2 applications, a non-adherent gauze was soaked with Nexodyn® AOS and applied on the wound surface, then covered with an all-purpose absorbent dressing.13

      GET IN TOUCH TO FIND OUT MORE